Target intelligence / Profile preview

Ubiquitin-like-conjugating enzyme ATG10 (ATG10)

Target
ATG10
Molecular classification
Enzyme, Ubiquitin-like conjugating enzyme (E2-like enzyme), Autophagy protein
01

Overview

Ubiquitin-like-conjugating enzyme ATG10 (ATG10) is a cytoplasmic protein acting as an E2-like enzyme. It plays a central role in the autophagy pathway by mediating the conjugation of ATG12 to ATG5, an essential step in autophagosome formation and maturation[2][3][4][7]. ATG10 has two isoforms in humans: the canonical long isoform and a shorter isoform (ATG10S), which may exert distinct effects on viral replication and autophagy flux[1]. ATG10 is implicated in neurodegenerative disorders, viral infections (notably hepatitis C), and cancer through its role in cellular degradation processes and cell survival[1][2]. It functions as part of the ubiquitin-like protein conjugation system, distinguishing it from traditional ubiquitin E2 enzymes via unique structural features[3]. ATG10 may serve as a therapeutic target for modulating autophagy in diseases where this process is dysregulated[1][2].

Other names
Autophagy related 10Autophagy-related protein 10ATG10APG10APG10LAPG10-likeDKFZP586I0418FLJ13954PP12616Ubiquitin-like-conjugating enzyme ATG10ATG10 autophagy related 10 homolog
02

Mechanism of action

Modulation of autophagy flux (restoration or inhibition); Inhibition or enhancement of ATG12-ATG5 conjugation; Promotion or suppression of autophagosome formation[1]

03

Biological functions

Autophagosome formationCatalysis of ATG12-ATG5 conjugation (essential for autophagy)Protein transportMacroautophagy regulationPositive regulation of protein modificationAdenovirus-mediated cell lysis
04

Disease associations

Neurodegeneration with brain iron accumulationFrontotemporal dementia and/or amyotrophic lateral sclerosisCancer (through autophagy regulation and virus interaction)Viral infection/replication (notably hepatitis C virus replication)Other neurodegenerative diseases (implicated in protein quality control and cell death processes)
05

Safety considerations

Excess or deficient autophagy may contribute to cancer progression, neurodegeneration, or impaired cellular homeostasis.Potential off-target effects or interference with global protein degradation and cell survival pathways.
06

Interacting drugs

No approved drugs listed as direct interactors; compounds targeting autophagy or E2-like enzymes might interact indirectly. Experimental compounds have been screened against ATG10[1].
07

Biomarkers

Autophagy markers: LC3B-II/I ratio, p62 proteinATG10 mRNA/protein expression levels (potential biomarker in cancers, viral infection, and neurodegenerative disease)

Beyond the preview

Go deeper on Ubiquitin-like-conjugating enzyme ATG10 (ATG10).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ubiquitin-like-conjugating enzyme ATG10 (ATG10).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call